Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models
Fiore Cattaruzza(Sanofi (United States)), Ann M. Kapoun(OncoMed (United States)), John Lewicki(OncoMed (United States)), Wan-Ching Yen(OncoMed (United States)), Marcus Fischer(St. Jude Children's Research Hospital), Gilbert O’Young(OncoMed (United States)), Pete Yeung(OncoMed (United States)), Alayne Brunner(OncoMed (United States)), Yuwang Liu(OncoMed (United States)), Min Wang(Academy of Military Medical Sciences), Cécile Chartier(Io Therapeutics (United States)), Austin Gurney(Australian Centre for Heart Health), Tim Hoey
Cited by 1
Related Papers
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
|Journal of Virology|1996|651
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
|Proceedings of the National Academy of Sciences|2012|630
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
|PLoS ONE|2008|582
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|431
IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1
|Journal of Biological Chemistry|2001|410